HFA Cardio Talk

With Jasper Brugts, Erasmus Medical Center Rotterdam, Rotterdam - The Netherlands and Floran Sahiti, University Hospital Würzburg and Comprehensive Heart Failure Center Würzburg, Würzburg - Germany. In this episode of the HFA Podcast Series, we will discuss telemonitoring in general, with a main focus on invasive monitoring in heart failure, the current evidence, and the advantages and disadvantages of the systems. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsors.

With Daniella Motta da Costa Dan, University of São Paulo - Brazil, and Marianna Adamo, University of Brescia - Italy. In this episode of HFA CardioTalk, Daniella Motta interviews Marianna Adamo on the controversies, consensus, and challenges surrounding revascularization in ischemic heart failure. The discussion highlights major clinical trials, emphasizes the importance of selecting appropriate patients, and examines the risks and benefits of revascularization in this context. Lastly, they address key updates from the latest ESC guidelines This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

In this discussion, Peter Van Der Meer, a heart failure expert from the University of Chronia, shares insights on peripartum cardiomyopathy, a serious condition affecting women late in pregnancy or post-delivery. He and Emmanouil Kampanieris delve into the challenges of diagnosing this condition, linking it to factors like preeclampsia and ethnic influences. They explore recovery rates, revealing that many patients regain heart function, and discuss bromocriptine as a potential treatment, emphasizing the need for further research and careful management.

With Nicolas Verheyen, Medical University of Graz, Graz - Austria, and Lars Kober, Rigshospitalet, Copenhagen University Hospital, Copenhagen - Denmark. In this episode of HFA CardioTalk, Nicolas Verheyen interviews Lars Kober on controversies in ICD/CRT implantation in non-ischemic cardiomyopathy for primary prevention. They focus in particular on the importance of selecting the right patients, and discuss biomarkers beyond left ventricular ejection fraction that may add value in predicting sudden death risk, and the need of randomized controlled trials with adequate endpoint selection to guide prophylactic ICD implantation. Related scientific paper: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2023 ESC Guidelines for the management of cardiomyopathies Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC) This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Jozine ter Maaten, University Medical Center Groningen - The Netherlands, Antonio Cannata, King's College London - UK, Mateusz Sokolski, Wroclaw Medical University - Poland, Henrike Arfsten, Medical University of Vienna - Austria, Stefan Anker, Charité University Hospital Berlin - Germany, Muthiuh Vaduganathan, Brigham and Women's hospital, Harvard Medical School Boston - USA, Cornelia Margineanu, Bucharest – Romania and Kengo Kusano, National Cerebral and Cardiovascular Center Hospital, Osaka - Japan. In this multivoice podcast from the ESC Congress 2024, the main results of three randomized controlled clinical trials (FINEARTS-HF, RESHAPE-HF2, and CRABL-HF) are discussed. Links to the papers: FINEARTS-HF RESHAPE-HF2 This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Guillaume Baudry, University Hospital of Brabois, Nancy - France, and Marco Metra, University of Brescia - Italy. In this episode of the HFA Cardiotalk podcast, Guillaume Baudry interviews Marco Metra, the lead author of the recent HFA clinical consensus statement on worsening heart failure. They delve into the definition of worsening heart failure, its prognosis, prevention strategies, and both acute and long-term management of this condition. Related scientific paper: Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology Risk of readmission and death after hospitalization for worsening heart failure: Role of post-discharge follow-up visits in a real-world study from the Grand Est Region of France Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

With Raja Ezman Faridz Bin Raja Shariff, Universiti Teknologi MARA, Selangor - Malaysia, and Kevin Damman, University Medical Centre Groningen - The Netherlands In this episode of the HFA Cardiotalk podcast, Ezman Shariff interviewed Kevin Damman – a key opinion leader in the field of cardiorenal interactions, to better understand the role natriuresis plays in the acute heart failure and what we have learnt from trials like PUSH-AHF and ENACT-HF, and the future direction of clinical trials in this field. This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

Experts from around the world discuss late-breaking clinical trials on heart failure, including hypertonic saline, echo substudy, and PRAISE-HFpEF results. The podcast dives into the evolving landscape of AF ablation as a primary treatment for heart failure patients, exploring its advantages over traditional drug therapies and highlighting the potential benefits for improved patient outcomes.

With Jozine M. ter Maaten, University Medical Centre Groningen, Groningen - Netherlands, Bart A. Mulder, 2022-2024, University Medical Centre Groningen, Groningen - Netherlands & Giuseppe Boriani, Polyclinic Modena University Hospital, Modena -Italy. Atrial fibrillation and heart failure often co-exist and influence each other. Treatment of AF specifically in the setting of heart failure can be challenging. Recently, new data emerged regarding the potential role of AF ablation in heart failure patients. In this podcast we discuss these in a special episode with a strong representation also from the EHRA Young highlighting the importance of interdisciplinary decision making in these patients. Recommended readings from this episode: CASTLE HTx CASTLE AF CABANA results in heart failure patients This 2024 HFA CardioTalk podcast series is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

Cardiologist Cornelia Margineanu from Bucharest, Romania, and Professor Thomas Felix Luscher from London, UK, discuss the future of heart failure specialists. They cover topics such as the evolution of heart failure treatment, challenges faced by future specialists, mentorship, career development, and exciting opportunities in cardiology.